Zydus Looks To NASH Trials In Turkey, Generic Vascepa Launch In The US

Generic Versions Of Revlimid And Trokendi Drive Record US Sales

 
• By Vibha Ravi
  
Earnings growth vector
Zydus Is Nurturing New Molecules For The Future Even As Generics Pay Off For Now • Source: Shutterstock

More from Strategy

More from Business